Dr Reddys Laboratories (RDY) Operating Expenses (2009 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Dr Reddys Laboratories was $153.79 billion, up 114.8% year-over-year; for the year ended Mar 31, 2026, it was $1.35 billion, down 99.5% from the prior year.

• Annual Operating Expenses shows a five-year compound annual growth rate of 4.6% (years ended Mar 2021 to Mar 2026).
• In prior years, Dr Reddys Laboratories' Operating Expenses was $260.83 billion in the year ended Mar 31, 2025, $1.15 billion in the year ended Mar 31, 2024 (+15.0%), $1 billion in the year ended Mar 31, 2023 (-10.1%) and $1.11 billion in the year ended Mar 31, 2022 (+3.2%).
• Quarterly Operating Expenses has run from a low of $178.89 million in the quarter ended Jun 30, 2022 to a high of $78.27 billion in the quarter ended Mar 31, 2026 over five years.
• On a year-over-year basis, Operating Expenses increased in four of the last six quarters, with growth averaging 10.9%.
• The strongest year-over-year quarter for Operating Expenses in the past five years was the quarter ended Jun 30, 2023, with growth of 49.1%; the weakest was the quarter ended Jun 30, 2022, with a decline of 30.9%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $78.27 billion (quarter ended Mar 31, 2026), $74.81 billion (quarter ended Dec 31, 2025) and $351.13 million (quarter ended Sep 30, 2025).